Rapid Micro Biosystems Inc
NASDAQ: RPID · HEALTHCARE · MEDICAL DEVICES
Updated 2026-06-05
Rapid Micro Biosystems Inc (RPID) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2010 | 2011 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.08M | $10.97M | $16.51M | $16.08M | $23.23M | $17.13M | $22.52M | $28.05M | $33.59M |
| Revenue growth (YoY) | — | -31.8% | +50.6% | -2.6% | +44.5% | -26.3% | +31.4% | +24.6% | +19.7% |
| Cost of revenue | $16.02M | $11.78M | $16.75M | $24.15M | $30.97M | $25.67M | $28.00M | $28.16M | $25.98M |
| Gross profit | $59000.00 | — | $-234000.00 | $-8.07M | $-7.74M | $-8.54M | $-5.49M | $-109000.00 | $7.61M |
| Gross margin | 0.4% | 0.0% | -1.4% | -50.2% | -33.3% | -49.8% | -24.4% | -0.4% | 22.7% |
| R&D | — | — | $5.43M | $6.53M | $9.78M | $12.87M | $12.82M | $14.60M | $13.60M |
| SG&A | $1.76M | $2.52M | $8.92M | $9.98M | $17.89M | $26.82M | $24.94M | $21.95M | $22.75M |
| Operating income | — | — | $-18.63M | $-30.54M | $-47.23M | $-63.22M | $-56.56M | $-49.92M | $-47.39M |
| Operating margin | 0.0% | 0.0% | -112.9% | -190.0% | -203.3% | -369.0% | -251.2% | -178.0% | -141.1% |
| EBITDA | — | — | $-16.87M | $-32.00M | $-45.70M | $-60.38M | $-53.46M | $-46.56M | $-44.14M |
| EBITDA margin | 0.0% | 0.0% | -102.2% | -199.0% | -196.7% | -352.4% | -237.4% | -166.0% | -131.4% |
| EBIT | — | — | $-18.37M | $-33.50M | $-47.23M | $-63.22M | $-56.56M | $-49.92M | $-47.39M |
| Interest expense | $0.00 | $0.00 | $2.38M | $3.45M | $2.65M | $1.78M | — | $40000.00 | $1.09M |
| Income tax | — | — | — | — | — | — | — | — | — |
| Effective tax rate | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | — | — | $-21.17M | $-37.08M | $-73.52M | $-60.81M | $-52.47M | $-46.89M | $-47.12M |
| Net income growth (YoY) | — | — | — | -75.1% | -98.3% | +17.3% | +13.7% | +10.6% | -0.5% |
| Profit margin | 0.0% | 0.0% | -128.2% | -230.6% | -316.5% | -354.9% | -233.0% | -167.2% | -140.3% |
Frequently asked questions
What is Rapid Micro Biosystems Inc's revenue?
Rapid Micro Biosystems Inc's trailing twelve-month revenue is $34.38M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is RPID?
In its most recent fiscal year, RPID ran a gross margin of 22.65%, an operating margin of -141.10%, and a net margin of -140.30%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does RPID generate?
RPID produced $-31.91M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is RPID's balance sheet healthy?
RPID holds $20.03M in cash and equivalents against $18.90M in long-term debt, on $33.21M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.